SCHEMBL741465

SCHEMBL741465

NC(=O)N(Cl)N=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27393378 0.69
SCHEMBL1123008 0.68
SCHEMBL28800262 0.67
SCHEMBL27452190 0.65 LMNA (0.39)
SCHEMBL26400712 0.65
SCHEMBL12657669 0.65
SCHEMBL28846524 0.65
Urea SCHEMBL8587560 0.63
SCHEMBL22686142 0.63
N-Methyl-N-Nitrosurea SCHEMBL38377 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2538944-B1 COMPOUND FOR TREATING BRAIN CANCER NIIKI PHARMA INC (US) 2014-10-22 EP claimed
US-20250195443-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof ANP TECHNOLOGIES, INC. (US) 2025-06-19 US disclosed
US-20250099432-A1 LIQUID PHARMACEUTICAL FORMULATION PROJECT PHARMACEUTICS GMBH (DE) 2025-03-27 US disclosed
US-12161631-B2 Liquid pharmaceutical formulation PROJECT PHARMACEUTICS GMBH (DE) 2024-12-10 US disclosed
EP-3773498-B1 LIQUID PHARMACEUTICAL FORMULATION PROJECT PHARMACEUTICS GMBH (DE) 2022-06-22 EP disclosed
CN-113398070-A Fractionated radiotherapy and chemotherapy using oxygen therapy 埃文·C·昂格尔 2021-09-17 CN disclosed
EP-3552617-B1 DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER UNIV EMORY (US) 2021-07-07 EP disclosed
US-20200323903-A1 DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER EMORY UNIVERSITY (US) 2020-10-15 US disclosed
US-10543233-B2 Drug resistant immunotherapy for treatment of a cancer EMORY UNIVERSITY (US) 2020-01-28 US disclosed
EP-3552617-A1 DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER Emory University (US) 2019-10-16 EP disclosed
EP-2429527-A1 NEW COMBINATION THERAPY IN TREATMENT OF CANCER AND FIBROTIC DISEASES Boehringer Ingelheim International GmbH (DE) 2012-03-21 EP disclosed
WO-2011134898-A1 NEW COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 WO disclosed
WO-2011053750-A2 DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER EMORY UNIVERSITY (US) 2011-05-05 WO disclosed
WO-2010130758-A1 NEW COMBINATION THERAPY IN TREATMENT OF CANCER AND FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 WO disclosed
WO-2010130757-A1 NEW COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-18 WO disclosed
WO-2010036936-A2 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2010-04-01 WO disclosed
US-6252048-B1 FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF CANCER ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE 2001-06-26 US disclosed
US-6046036-A FOR INCREASING SURVIVAL RATE OF NON-TARGET CELLS SUCH AS HEMATOPOIETIC CELLS WHEN CONTACTED WITH ANTICARCINOGENIC/DNA-DAMAGING AGENTS DURING MULTIAGENT CHEMOTHERAPY PROTOCOLS OR IN FANCONI'S ANEMIA ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) 2000-04-04 US disclosed
WO-1999025386-A1 delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE CASE WESTERN RESERVE UNIVERSITY (US) 1999-05-27 WO disclosed
WO-1998017684-A2 DNA SEQUENCES ENCODING FUSIONS OF DNA REPAIR PROTEINS AND USES THEREOF ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) 1998-04-30 WO disclosed